The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
XL BCL3 BA
Break Apart Probe
- Order Number
- Package Size
- 100 µl
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. The clinical course is heterogeneous and ranges from good outcome to very aggressive and fast progressing disease. CLL is not characterized by a well-defined chromosomal translocation as many other lymphoid neoplasms. The most frequent aberrations are deletions on 6q21 (3-6%), 11q22-23 (5-20%), 13q14.3 (>50%) or 17q13.1 (3-8%) and trisomy 12 (10-20%). The recurrent t(14;19)(q32.3;q13.3) is a rare event with an incidence of <0.1% in B-cell neoplasms and is often associated with trisomy 12 or a complex karyotype. It is considered as a poor prognostic marker in CLL with inferior outcome. The translocation juxtaposes BCL3 with the immunoglobulin heavy chain gene region on chromosome 14 resulting in overexpression of BCL3. BCL3 is an oncogene and is involved in the regulation of NF-kappa-B target genes. Since it is difficult to obtain metaphases from CLL patients, interphase FISH offers great advantage over conventional cytogenetics.
- Chronic Lymphocytic Leukemia (CLL)
Two green-orange colocalization/fusion signals (2GO).
Aberrant Cell (typical results):
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the relevant locus.
- Michaux et al (1996) Genes Chrom Can 15:38-47
- Huh et al (2011) Am J Clin Pathol 135:686-696
- Puiggros et al (2014) Biomed Res Int 2014:Article ID 435983